BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors. 2023

Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, PR China.

Tropomyosin receptor kinases (TRKs) are effective targets for anti-cancer drug discovery. The first-generation type I TRKs inhibitors, larotrectinib and entrectinib, exhibit durable disease control in the clinic. The emergence of acquired resistance mediated by secondary mutations in the TRKs domain significantly reduces the therapeutic efficacy of these two drugs, indicating an unmet clinical need. In this study, we designed a potent and orally bioavailable TRK inhibitor, compound 24b, using a molecular hybridization strategy. Compound 24b exhibited significant inhibitory potency against multiple TRK mutants in both biochemical and cellular assays. Furthermore, compound 24b induced apoptosis of Ba/F3-TRKAG595R and Ba/F3-TRKAG667C cells in a dose-dependent manner. Additionally, compound 24b exhibited moderate kinase selectivity. In vitro stability revealed that compound 24b showed excellent plasma stability (t1/2 > 289.1 min) and moderate liver microsomal stability (t1/2 = 44.3 min). Pharmacokinetic studies have revealed that compound 24b is an orally bioavailable TRK inhibitor with a good oral bioavailability of 116.07%. These results indicate that compound 24b be used as a lead molecule for further modifications to overcome drug-resistant mutants of TRK.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D020917 Receptor, trkA A protein-tyrosine kinase receptor that is specific for NERVE GROWTH FACTOR; NEUROTROPHIN 3; neurotrophin 4, neurotrophin 5. It plays a crucial role in pain sensation and thermoregulation in humans. Gene mutations that cause loss of receptor function are associated with CONGENITAL INSENSITIVITY TO PAIN WITH ANHIDROSIS, while gene rearrangements that activate the protein-tyrosine kinase function are associated with tumorigenesis. NTRK1 Receptor,Proto-Oncogene Protein trk,Receptor, Neurotrophic Tyrosine Kinase Type 1,gp140(c-TRK),trk Proto-Oncogene Protein,trkA Receptor,Neurotrophic Tyrosine Kinase Receptor Type 1,Proto-Oncogene Products c-trk,c-trk Protein,gp140 c-trk,p140-trkA,trk1 Transforming Tryrosine Kinase,Proto Oncogene Products c trk,Proto Oncogene Protein trk,Proto-Oncogene Protein, trk,Receptor, NTRK1,c trk Protein,c-trk, Proto-Oncogene Products,c-trk, gp140,gp140 c trk,p140 trkA,trk Proto Oncogene Protein,trk, Proto-Oncogene Protein

Related Publications

Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, Synthesis, and Biological Evaluation of 3-Substituted-Indolin-2-One Derivatives as Potent Anti-Inflammatory Agents.
January 2023, International journal of molecular sciences,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors.
March 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
December 2020, European journal of medicinal chemistry,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds.
August 2017, Bioorganic & medicinal chemistry letters,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
February 2017, European journal of medicinal chemistry,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis and biological evaluation of novel bromophenol derivatives incorporating indolin-2-one moiety as potential anticancer agents.
February 2015, Marine drugs,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis, and biological evaluation of novel pyrimidin-2-amine derivatives as potent PLK4 inhibitors.
September 2023, RSC medicinal chemistry,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design of new small molecules derived from indolin-2-one as potent TRKs inhibitors using a computer-aided drug design approach.
January 2024, Journal of biomolecular structure & dynamics,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.
December 2018, Bioorganic & medicinal chemistry letters,
Qiaohua Qin, and Qinglin Fu, and Xin Wang, and Ruicheng Lv, and Shuyu Lu, and Zhiqiang Guo, and Tianxiao Wu, and Yin Sun, and Yixiang Sun, and Nian Liu, and Dongmei Zhao, and Maosheng Cheng
Design, Synthesis, and Biological Evaluation of Novel Acylhydrazone Derivatives as Potent Neuraminidase Inhibitors.
September 2020, ACS medicinal chemistry letters,
Copied contents to your clipboard!